Deloitte health report projects a deceleration in health spending, likely creating a U.S. $3.5 trillion “well-being dividend” by 2040. The report shares what the future of health could look like: new business models, emerging technologies, and highly engaged consumers.
Healthcare spending in the United States topped $3.8 trillion dollars in 2019 — nearly 18% of the gross domestic product (GDP) — as projected by the CMS Office of the Actuary.
Prior to the COVID-19 pandemic, CMS had projected health spending would continue to grow at a rate of 5.3% a year, reaching nearly $6.2 trillion by 2028. If those increases were to continue unabated over the next 20 years, health spending could reach a staggering $11.8 trillion by 2040.
However, finance firm Deloitte released a report recently predicting health spending as a percentage of the GDP will decelerate over the next 20 years.
In the new Deloitte report, "Breaking the cost curve: Deloitte predicts health spending as a percentage of GDP will decelerate over the next 20 years," it anticipates that emerging technologies, an ability to cure and prevent disease (or detect disease in the earliest stages), and highly engaged consumers will lead to a deceleration of health spending between now and 2040.
The report predicted three separate areas will take shape by 2040:
Get the latest industry news, event updates, and more from Managed healthcare Executive.
A Conversation with Jeremiah Johnson, Executive Director of PrEP4All
July 25th 2025Jeremiah Johnson, executive director of PrEP4All, an organization committed to HIV prevention and care, talks about the importance of preexposure anaphylaxis and why he’s hesitant to jump on the Lenacapavir breakthrough bandwagon.
Read More
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More